Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime

Ryan K. Shields, Alina Iovleva, Ellen G. Kline, Akito Kawai, Christi L. McElheny, Yohei Doi

研究成果: Article査読

8 被引用数 (Scopus)

抄録

We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

本文言語English
ページ(範囲)2713-2716
ページ数4
ジャーナルClinical Infectious Diseases
71
10
DOI
出版ステータスPublished - 15-11-2020

All Science Journal Classification (ASJC) codes

  • 微生物学(医療)
  • 感染症

フィンガープリント

「Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル